BUY Zydus Lifesciences Limited — Jefferies India
byJefferies IndiaHorizon: NA (inferred 1 year)28 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth
NewsNdtv-Profit·11 Aug · today
Zydus Lifesciences Ltd has launched REVAHALE, which is India's first once-daily nebulised LAMA medication for COPD.
BSE · Company Update·10 Aug · today
1 other SEBI-registered advisor has an active long-term BUY call on this stock, issued in the last 14 days
Advisor consensus · same horizon·11 Aug · today
Zydus gets USFDA nod for surgical imaging drug, may get 6-month monopoly in $125 million US market
NewsCnbc-Tv18·4 Aug · 6d ago
Zydus Lifesciences Ltd announced final approval from the USFDA for Indocyanine Green for Injection, including 180-days CGT exclusivity.
BSE · Company Update·4 Aug · 6d ago
Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price
NewsNdtv-Profit·11 Aug · today
Market Pulse: Key triggers to watch before the August 11 trading session
NewsCnbc-Tv18·10 Aug · today
Zydus Lifesciences suspends some Ahmedabad operations due to heavy rain, resumes activity
NewsCnbc-Tv18·25 Jul · 2w ago
Corporate Actions This Week: Angel One, Bharti Airtel, Hero MotoCorp, Zydus Lifesciences And Pidilite Industries | Full List
NewsNdtv-Profit·19 Jul · 3w ago
Zydus Lifesciences received an order from the Superintendent of Stamps, Gandhinagar, demanding recovery of ₹53.47 million in deficient stamp duty and ₹55.07 million in penalties, totaling ₹108.54 mill
BSE · Company Update·29 Jul · 2w ago
The exchange sought clarification from Zydus Lifesciences Ltd regarding a media report about a Delhi High Court order temporarily restricting the supply of its cancer drug Ikra in a patent dispute.
BSE · Company Update·14 Jul · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Zydus Lifesciences
- BUY — Manas Jaiswal22 Oct 2026 · ~3 months · target ₹1,160 · SL hit
- BUY — Vikas Sethi, Sethi Finmart22 Oct 2026 · Same day · target ₹1,130 · SL hit
- BUY — Siddharth Rai Mangala15 Oct 2026 · ~2 weeks · target ₹1,165 · SL hit
- BUY — Ansh Jogendra Bhilwar13 Oct 2026 · Same day · target ₹1,166 · SL hit
- BUY — Kavita Jain, Arihant Capital Markets6 Oct 2026 · ~2 weeks · target ₹1,175 · SL hit
More from Jefferies India
- BUY SAGILITY23 Oct 2026 · ~1 year · target ₹59 · Active
- BUY Colgate Palmolive (India)23 Oct 2026 · ~1 year · target ₹2,000 · Active
- BUY Swiggy23 Oct 2026 · ~1 year · target ₹330 · Active
- BUY JSW Infrastructure23 Oct 2026 · ~1 year · target ₹400 · Active
- BUY Vishal Mega Mart22 Oct 2026 · ~1 year · target ₹130 · Active

